Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 2 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 2 of 10.)

DateHeadlineEventSource5-minTo close
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomaPress releasePR Newswire-0.30%-2.55%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.23%-0.04%
FDA approves label expansion, cementing TREMFYA® as the only IL-23 inhibitor proven to help stop further joint damagePress releasePR Newswire-0.30%-2.55%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR-0.02%-0.09%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire-0.02%-0.09%
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction PortfolioPress releaseBusiness Wire-0.49%-1.21%
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSISPress releaseBusiness Wire-0.49%-1.21%
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovationPress releasePR Newswire+0.38%-1.76%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR-0.65%-0.09%
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL CatheterPress releaseBusiness Wire-0.04%+0.54%
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPPress releasePR Newswire+0.10%+0.05%
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferencePress releaseBusiness Wire-0.04%+0.54%
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for RemissionPress releasePR Newswire-0.70%-1.01%
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic SystemPress releaseBusiness Wire-0.01%+0.07%
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseasePress releasePR Newswire-0.01%+0.07%
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's diseasePress releasePR Newswire-0.01%+0.07%
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisPress releasePR Newswire-0.11%-0.58%
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor RelationsPress releaseBusiness Wire+0.21%+0.83%
Form 8-K JOHNSON & JOHNSON For: Apr 23SEC filing · Form 8-KSEC EDGAR+0.02%+0.03%
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)Press releasePR Newswire+0.58%-0.19%
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions ConferencePress releaseBusiness Wire+0.02%+0.03%
Form 10-Q JOHNSON & JOHNSON For: Mar 29SEC filing · Form 10-QSEC EDGAR-0.13%+1.17%
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)Press releasePR Newswire+0.47%-0.04%
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026Press releaseBusiness Wire-1.02%-1.39%
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire+0.47%-0.04%
Imaging science research gives new clarity on what color helps eyes focus bestPress releasePR Web-0.31%-0.54%
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare ConferencePress releaseBusiness Wire-0.30%-1.21%
Form 8-K JOHNSON & JOHNSON For: Apr 14SEC filing · Form 8-KSEC EDGAR+1.62%+2.61%
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%Press releaseBusiness Wire+1.62%+2.61%
Johnson & Johnson reports Q1 2026 results, raises 2026 outlookPress releaseBusiness Wire+1.62%+2.61%
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of VisionPress releaseBusiness Wire-1.25%-1.46%
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in EuropePress releaseBusiness Wire-1.35%-0.98%
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasisPress releasePR Newswire-1.07%-0.43%
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptidePress releasePR Newswire+0.27%-0.25%
Form 13F-HR/A JOHNSON & JOHNSON For: Dec 31SEC filing · Form 13F-HRSEC EDGAR+0.00%+0.08%
Form 13F-HR/A JOHNSON & JOHNSON For: Sep 30SEC filing · Form 13F-HRSEC EDGAR-0.20%-0.08%
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancerPress releasePR Newswire+0.07%-0.70%
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract PatientsPress releaseBusiness Wire+0.04%+0.24%
Form ARS JOHNSON & JOHNSON For: Dec 28SEC filing · Form ARSSEC EDGAR-0.07%+0.13%
Form DEF 14A JOHNSON & JOHNSON For: Mar 11SEC filing · Form DEFSEC EDGAR-0.07%+0.13%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-0.07%+0.13%
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second LinePress releasePR Newswire+0.11%+0.11%
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)Press releasePR Newswire-0.46%-0.02%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire-0.46%-0.02%
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancerPress releasePR Newswire-0.12%+0.22%
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)Press releasePR Newswire+0.50%+0.13%
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 yearsPress releasePR Newswire+0.64%+0.91%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancerPress releasePR Newswire-0.19%-1.61%
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in PennsylvaniaPress releaseBusiness Wire-0.18%+0.23%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancerPress releasePR Newswire+0.55%+0.86%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground